Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mia Kontio is active.

Publication


Featured researches published by Mia Kontio.


The Journal of Infectious Diseases | 2012

Waning Antibody Levels and Avidity: Implications for MMR Vaccine-Induced Protection

Mia Kontio; Sari Jokinen; Mikko Paunio; Heikki Peltola; Irja Davidkin

BACKGROUND The measles-mumps-rubella (MMR) vaccine is effective in eliciting a good antibody response. In addition to the amount of antibodies, the avidity of these antibodies might be important in protecting against disease. METHODS The amount of circulating antibodies for measles, mumps, and rubella was measured with enzyme immunoassays, and the avidity of these antibodies was determined by urea dissociation. Three groups of twice-MMR-vaccinated individuals and 1 group of naturally infected individuals were studied. One vaccinated group (n = 71) was studied 6 months and 20 years after a second MMR vaccination. RESULTS The antibody avidity indexes were high for measles and rubella but low for mumps. Twenty years after a second MMR vaccination, antibody levels for all 3 viruses waned. Also, the mean avidity index decreased by 8% for measles, 24% for mumps, and remained unchanged for rubella. Antibody avidity correlated with antibody concentration for measles. There was partial correlation for rubella and no correlation for mumps. CONCLUSIONS Measles and rubella induced high-avidity antibodies and mumps induced low-avidity antibodies after both vaccination and natural infection. Waning of both the concentration as well as the avidity of antibodies might contribute to measles and mumps infections in twice-MMR-vaccinated individuals.


Eurosurveillance | 2013

Ongoing multi-strain food-borne hepatitis A outbreak with frozen berries as suspected vehicle: four Nordic countries affected, October 2012 to April 2013.

S. Gillesberg Lassen; Soborg B; Sofie Midgley; Anneke Steens; Line Vold; Kathrine Stene-Johansen; Ruska Rimhanen-Finne; Mia Kontio; M Löfdahl; Lena Sundqvist; M. Edelstein; Tenna Jensen; H.T. Vestergaard; Thea Kølsen Fischer; Kåre Mølbak; Steen Ethelberg

A food-borne outbreak of hepatitis A in Denmark was notified to other countries on 1 March 2013. A case-control study identified frozen berries eaten in smoothies as potential vehicle. In the following weeks, Finland, Norway and Sweden also identified an increased number of hepatitis A patients without travel history. Most cases reported having eaten frozen berries at the time of exposure. By 17 April, 71 cases were notified in the four countries. No specific type of berry, brand or origin of berries has yet been identified. .


Expert Review of Vaccines | 2010

MMR vaccination and disease elimination: the Finnish experience.

Irja Davidkin; Mia Kontio; Mikko Paunio; Heikki Peltola

Measles, mumps and rubella (MMR) vaccinations have been included in Finland’s national vaccination program as a two-dose schedule since 1982. Owing to the high (>95%) coverage of vaccinations, indigenous MMR diseases were eliminated from Finland by the mid-1990s. In 1982, the incidence of measles, mumps and rubella was 105, 43 and 64 per 100,000 population, respectively, but declined to 0.1 per 100,000 population for all MMR diseases in 1995. Since then, the few cases of measles, mumps and rubella imported annually have not caused any outbreaks. Several research projects that started along with the vaccination campaign have provided important support throughout the program. The vaccine was proven to be safe, immunogenic and effective. Antibody follow-up has revealed that MMR vaccine-induced antibodies wane over time, and concerns have arisen about the continuation of this good situation. High vaccination coverage, enhanced surveillance and preparedness to administer additional doses when needed are key factors for future success. Here we present an overview of MMR vaccinations and the Finnish experience of the MMR disease elimination process, and we describe surveillance activities in the era following elimination in Finland.


Journal of Medical Virology | 2012

Increased circulation of hepatitis A virus genotype IIIA over the last decade in St Petersburg, Russia

Sergey Mukomolov; Mia Kontio; Nina Zheleznova; Sari Jokinen; Eugenia Sinayskaya; Anna Stalevskaya; Irja Davidkin

The current study, covering the period 2004–2009, is a part of long‐term monitoring for hepatitis A virus (HAV) strains circulating in St Petersburg, Russia. The HAV RNA was isolated directly from the sera of hepatitis A patients and RT‐PCR was carried out using primer pairs for VP1/2A and VP1 genomic regions. PCR products were sequenced and 324 nucleotides from VP1/2A and 332 from the VP1 region were used for phylogenetic analysis. The results show that the IA subtype was the most common circulating subtype during the follow‐up period, as found in the previous study: almost 90% of the isolated HAV strains belonged to the IA subtype. The large hepatitis A food‐borne outbreak in St Petersburg in 2005 was caused by HAV IA. However, the proportion of HAV isolates belonging to subtype IIIA significantly increased in the period 2001–2009 (7.9%) compared to the period 1997–2000 (none found). The subtype IIIA was first found in St Petersburg in 2001 among a group of intravenous drug users. The increase in its circulation during the decade suggests that this previously unusual genotype has been permanently introduced into the general population of St Petersburg. These results indicate the usefulness of molecular epidemiological methods for studying changes in the circulation of HAV strains. J. Med. Virol. 84:1528–1534, 2012.


The Journal of Infectious Diseases | 2016

Similar antibody levels in 3-year old children vaccinated against measles mumps and rubella at the age of 12 months or 18 months

Mia Kontio; Arto A. Palmu; Ritva Syrjänen; Mika Lahdenkari; Esa Ruokokoski; Irja Davidkin; Outi Vaarala; Merit Melin

BACKGROUND Measles-mumps-rubella (MMR) vaccinations have been offered to Finnish children at 14-18 months and 6 years of age. In May 2011, the recommended age for the first vaccine dose was lowered to 12 months because of the European measles epidemic. METHODS Fingertip capillary blood samples were collected from 3-year-old Finnish children vaccinated once with MMR vaccine at 11-19 months of age. The immunoglobulin G (IgG) antibodies to all 3 MMR antigens were measured with enzyme-linked immunosorbent assay. Neutralizing antibodies and the avidity of antibodies were measured for measles virus. RESULTS From April through October 2013, 187 children were enrolled. Equally high proportions of the samples were seropositive for measles virus, mumps virus, or rubella virus antibodies, and there were no significant differences in the IgG antibody concentrations in children vaccinated at 11-13 months of age, compared with those vaccinated at 17-19 months of age. However, among children vaccinated at 11-13 months of age, boys had lower antibody concentrations than girls. Neutralizing measles virus antibody titers were above the threshold for protective immunity in all 78 samples analyzed. The measles virus antibody avidity indexes were high for all children. CONCLUSIONS MMR induces similar antibody responses in 12-month-old children as compared to 18-month-old children, but in boys increasing age appears to improve the antibody responses.


WOS | 2018

Travel-associated hepatitis A in Europe, 2009 to 2015

Julien Beauté; Therese Westrell; Daniela Schmid; Luise Müller; Jevgenia Epstein; Mia Kontio; Elisabeth Couturier; Mirko Faber; Kassiani Mellou; Maria-Louise Borg; I. H. M. Friesema; Line Vold; Ettore Severi

Background Travel to countries with high or intermediate hepatitis A virus (HAV) endemicity is a risk factor for infection in residents of countries with low HAV endemicity. Aim: The objective of this study was to estimate the risk for hepatitis A among European travellers using surveillance and travel denominator data. Methods: We retrieved hepatitis A surveillance data from 13 European Union (EU)/ European Economic Area (EEA) countries with comprehensive surveillance systems and travel denominator data from the Statistical Office of the European Union. A travel-associated case of hepatitis A was defined as any case reported as imported. Results: From 2009 to 2015, the 13 countries reported 18,839 confirmed cases of hepatitis A, of which 5,233 (27.8%) were travel-associated. Of these, 39.8% were among children younger than 15 years. The overall risk associated with travel abroad decreased over the period at an annual rate of 3.7% (95% confidence interval (CI): 0.7–2.7) from 0.70 cases per million nights in 2009 to 0.51 in 2015. The highest risk was observed in travellers to Africa (2.11 cases per million nights). Cases more likely to be reported as travel-associated were male and of younger age (< 25 years). Conclusion: Travel is still a major risk factor for HAV infection in the EU/EEA, although the risk of infection may have slightly decreased in recent years. Children younger than 15 years accounted for a large proportion of cases and should be prioritised for vaccination.


Eurosurveillance | 2017

A cluster of measles linked to an imported case, Finland, 2017

E. Seppala; V. Zoldi; S. Vuorinen; S. Murtopuro; U. Elonsalo; J. van Beek; Anu Haveri; Mia Kontio; Carita Savolainen-Kopra; Taneli Puumalainen; Jussi Sane

One imported and five secondary cases of measles were detected in Finland between June and August 2017. The measles sequences available for five laboratory-confirmed cases were identical and belonged to serotype D8. The large number of potentially exposed Finnish and foreign individuals called for close cooperation of national and international public health authorities and other stakeholders. Raising awareness among healthcare providers and ensuring universally high vaccination coverage is crucial to prevent future clusters and outbreaks.


Journal of Clinical Microbiology | 2011

VALIDATION AND DIAGNOSTIC APPLICATION OF NS AND HA GENE-SPECIFIC REAL-TIME RT-PCR ASSAYS FOR THE DETECTION OF 2009 PANDEMIC INFLUENZA A(H1N1) VIRUSES IN CLINICAL SPECIMENS

Esa Rönkkö; Niina Ikonen; Mia Kontio; Minna Haanpää; Hannimari Kallio-Kokko; Laura Mannonen; Maija Lappalainen; Ilkka Julkunen; Thedi Ziegler

ABSTRACT Real-time reverse transcription-PCR assays specific for the nonstructural (NS) and hemagglutinin (HA) genes of the 2009 pandemic influenza A (H1N1) virus were developed and evaluated with clinical samples from infected patients. The tests are characterized by high sensitivity and specificity and performed well throughout the first year of the 2009 pandemic.


WOS | 2013

Validation and Diagnostic Application of NS and HA Gene-Specific Real-Time Reverse Transcription-PCR Assays for Detection of 2009 Pandemic Influenza A (H1N1) Viruses in Clinical Specimens

Esa Rönkkö; Niina Ikonen; Mia Kontio; Minna Haanpää; Hannimari Kallio-Kokko; Laura Mannonen; Maija Lappalainen; Ilkka Julkunen; Thedi Ziegler

ABSTRACT Real-time reverse transcription-PCR assays specific for the nonstructural (NS) and hemagglutinin (HA) genes of the 2009 pandemic influenza A (H1N1) virus were developed and evaluated with clinical samples from infected patients. The tests are characterized by high sensitivity and specificity and performed well throughout the first year of the 2009 pandemic.


WOS | 2013

MMR vaccination and disease elimination: the Finnish experience

Irja Davidkin; Mia Kontio; Mikko Paunio; Heikki Peltola

Collaboration


Dive into the Mia Kontio's collaboration.

Top Co-Authors

Avatar

Irja Davidkin

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar

Lena Sundqvist

Public Health Agency of Sweden

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Esa Rönkkö

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar

Jussi Sane

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Markku Kuusi

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Minna Haanpää

National Institute for Health and Welfare

View shared research outputs
Researchain Logo
Decentralizing Knowledge